AbbVie Inc. (ABBV)
AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence
AbbVie's (ABBV) acquisition of Celsius Therapeutics is set to add the latter's lead pipeline candidate, CEL383, a potential first-in-class TREM1 inhibitor, to ABBV's pipeline.
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Can AbbVie Stock Keep Outpacing the S&P 500?
AbbVie's shares have outshined the red-hot S&P 500 over the prior 12 months. Even so, the drugmaker's shares remain in bargain territory.
AbbVie (ABBV) Parkinson's Candidate Faces 2nd FDA Rejection
AbbVie (ABBV) issues the second CRL for Parkinson's disease medicine, ABBV-951, based on some observations on inspection of one of its third-party manufacturing facilities.
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
AbbVie (ABBV) reachead $170.75 at the closing of the latest trading day, reflecting a -1.15% change compared to its last close.
US FDA declines to approve AbbVie's Parkinson's disease therapy
AbbVie said on Tuesday the U.S. Food and Drug Administration has rejected the company's marketing application for its therapy to treat motor fluctuations in adults with advanced Parkinson's disease.
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
AbbVie is one of the world's largest pharmaceutical companies and one of the fastest dividend raisers in its industry. Shares of business development company Ares Capital offer a yield above 9% at recent prices.
Hot Summer Dividends: 3 Sizzling Stocks to Buy for Reliable Income
With the stock market near all-time highs, I'm looking forward to the next market crash. Yes, I want the stock market to fall and fall hard.
3 Biotech Stocks to Buy Now: June 2024
Recently, the biotech industry has taken a bit of a slower stance toward growth. With the Covid-19 pandemic in the rearview mirror, the focus of major pharmaceutical developers and biotech companies shifted back toward chronic diseases like diabetes, cancer, and heart disease.
AbbVie stock price forecast: $200 on the cards?
On June 20, 2024, AbbVie Inc. (NYSE:ABBV) announced that it has received FDA approval for expanding the use of its interleukin-23 (IL-23) inhibitor, Skyrizi, to treat adults with moderate to severe ulcerative colitis. This approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S.
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for June 2024
As we move into June, I've identified three top retirement stocks that could be excellent long-term investments. While many investors have been focused on the cryptocurrency market, as Bitcoin ( BTC-USD ) aims for another new all-time high.
